SUDA Pharmaceuticals (ASX SUD), a company focused on oro-mucosal drug delivery, has announced the appointment of Paul Hopper as interim executive chairman to succeed Stephen Carter.
Mr Hopper was the non-executive chairman. The company announced the resignation of Mr Carter after nearly nine years on the board and management team.
“Stephen has taken the company from a one product company into owning the platform technology of OroMist™, with multiple R&D projects and several on the verge of commercialisation,” said Mr Hopper.
“He leaves SUDA in a very strong position for future growth and we sincerely thank him for his contributions and leadership during his tenure.”
The company said Mr Carter will continue to provide technical assistance on a consulting basis to help ensure a smooth handover to the new CEO.
The board said it has begun a search for a new CEO.